BCAL Diagnostics Limited (ASX:BDX)

ALERT: Price-sensitive ASX Announcement for BDX

Current share price for BDX : $0.079 -0.036 (-31.30%)⁺

Announcement

Shareholder Update

Release

5 Feb 2026 8:24AM

Price at Release

$0.115

Full Release

Summary

BCAL Diagnostics Limited, listed on the ASX as BDX, announced the commercial launch of its Avantect® blood-based cancer diagnostic tests for pancreatic and ovarian cancers, featuring collaboration with Sonic Healthcare for distribution across New South Wales, Queensland, and Victoria. With a pricing strategy that ensures a positive gross margin, BCAL is also working with advocacy groups to support reimbursement pathways. The company has established necessary infrastructure to support testing volumes and anticipates revenue of $300,000 in CY2026. Additionally, BCAL continues to progress with its BREASTESTplus™ test, focusing on market expansion and GP education. The company is active in policy engagement, participating in events to advocate for early cancer detection tests.

Key Points

Commercial launch of Avantect® Pancreatic and Ovarian cancer testing at Sydney Breast Clinic.
BCAL working with Sonic Healthcare to roll out testing through pathology sites in NSW, QLD, and VIC.
BCAL's commercial model is based on a per-test revenue structure with current unit test prices generating a positive gross margin.
Collaboration with Pancare Foundation and Pankind to support reimbursement pathways.
Establishment of laboratory, logistics, and reporting processes to support commercial testing volumes.
Expectations for CY2026 revenue for Avantect tests of $300,000, aligning with previous guidance.
Progress on BREASTESTplus, with 108 tests sold during Q2 FY26 and a focus on GP education.
Engagement in reimbursement and policy discussions, including participation in events at Parliament House.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.